ABSTRACT
OBJECTIVES: to assess the concentration of heavy metals in the nails of children aged 6-9 years residing in Forlì (Emilia-Romagna Region, Northern Italy). DESIGN: biomonitoring survey. SETTING AND PARTICIPANTS: in March 2017, a total of 236 toenail samples were collected, 221 of them were eligible; the concentration of 23 metals were measured in these eligible samples. MAIN OUTCOME MEASURES: a spatial analysis was conducted, considering home addresses as grouped in the four macroareas in which the local territory is administratively divided. RESULTS: In the two North-Center and East areas - which include various industrial operations, two waste incinerators and a motorway - the total concentration of all metals resulted 60% higher than in the West and South areas. Given the lack of Italian reference values, comparison tests between areas were performed for aluminum (Al), cadmium (Cd), iron (Fe), manganese (Mn), copper (Cu), and zinc (Zn), which concentrations were detectable in over 50% of the subjects. Higher concentrations were observed in the East area compared with the other areas, with statistical significance for Al (vs North-Center), Cu and Zn (vs West), and Al and Mn (vs South). Further comparisons showed significantly higher concentration of Cu in Nord-Center vs West, which in turn had higher concentrations of Zn compared to the Southern area. By applying a Tobit regression to evaluate possible confounding factors, a marginally significant correlation resulted for the nail concentration of Mn among children practicing outdoor sports and eating locally grown vegetables. The consumption of local vegetables was at the limits of significance also for Cd. CONCLUSIONS: the data obtained came from a voluntary and crowdfunded study and suggest a possible relationship between the exposure to air pollutants and subsequent accumulation of metals in the nails. Further and more detailed epidemiological studies are warranted to identify the exposure sources and to yield preventive intervention.
Subject(s)
Environmental Exposure/analysis , Metals, Heavy , Nails , Child , Environmental Monitoring , Humans , Italy/epidemiology , Metals, Heavy/analysis , Nails/chemistryABSTRACT
The impact of waste incinerators is usually examined by measuring environmental pollutants. Biomonitoring has been limited, until now, to few metals and to adults. We explored accumulation of a comprehensive panel of metals in children free-living in an urban area hosting two waste incinerators. Children were divided by georeferentiation in exposed and control groups, and toenail concentrations of 23 metals were thereafter assessed. The percentage of children having toenail metal concentrations above the limit of detection was higher in exposed children than in controls for Al, Ba, Mn, Cu, and V. Exposed children had higher absolute concentrations of Ba, Mn, Cu, and V, as compared with those living in the reference area. The Tobit regression identified living in the exposed area as a significant predictor of Ba, Ni, Cu, Mn, and V concentrations, after adjusting for covariates. The concentrations of Ba, Mn, Ni, and Cu correlated with each other, suggesting a possible common source of emission. Exposure to emissions derived from waste incinerators in an urban setting can lead to body accumulation of specific metals in children. Toenail metal concentration should be considered a noninvasive and adequate biomonitoring tool and an early warning indicator which should integrate the environmental monitoring of pollutants.
Subject(s)
Biological Monitoring , Environmental Pollutants , Incineration , Metals, Heavy , Adult , Child , Environmental Exposure , Environmental Monitoring , Humans , Metals , Urban PopulationSubject(s)
Neoplasms/epidemiology , Adolescent , Carcinogenesis , Causality , Child , Child, Preschool , Humans , Incidence , Infant , Italy/epidemiology , Neoplasms/etiology , Registries , UncertaintyABSTRACT
Epidemiological data should support policy makers in their decisions. Misjudgments in data interpretation can justify the preservation of the existing situation and the lack of decision about health and environment safeguard. In the SENTIERI study on Italian polluted sites, women mortality results significantly lower than the regional mean in 11 sites in 44. The authors of this paper think that these data depend on the different impact of pollution on the population of a site, as witnessed by the cases of Brindisi and Manfredonia (Southern Italy). It is now necessary to conduct studies at suburban level integrating mortality data with other available health data.
Subject(s)
Environmental Exposure , Environmental Pollution , Hazardous Substances , Humans , Italy/epidemiologySubject(s)
Incineration , Public Health , Environmental Exposure , Humans , Incineration/economics , ItalyABSTRACT
Baseline anemia is a relevant prognostic factor in the overall population of non-Hodgkin's lymphoma (NHL) patients, and studies focusing on elderly NHL are awaited. We conducted a pooled analysis of a cohort of comparable patients enrolled (1993 - 2001) in three multicenter clinical trials on use of a MACOP-B-like regimen (VNCOP-B) for front-line treatment of elderly aggressive NHL. Models of Cox's proportional hazards regression analysis of prognostic value of pre-/post-treatment hemoglobin values in terms of 5-year overall survival included age, sex, initial tumor staging and response to treatment. Of the 168 patients screened, 16 were excluded due to missing data or lack of 5-year follow-up. In addition to achievement of complete/partial remission (adjusted relative risk [RR], 0.215; p = 0.0001) and advanced stage (II-IV vs. I - II; adjusted RR, 1.55; p = 0.0023), post-treatment hemoglobin values were an independent predictor of survival (adjusted RR per 1-g/dL increment, 0.76; p = 0.0041). In the present analysis, pretreatment hemoglobin values were associated with only marginal risk reduction (adjusted RR per 1-g/dL increment, 0.985; p = 0.049). Post-treatment hemoglobin values appear to provide a strong independent predictor of 5-year survival in elderly aggressive NHL, supporting the potential role of anemia correction in this group of patients.
Subject(s)
Anemia/complications , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/drug therapy , Aged , Aged, 80 and over , Anemia/pathology , Female , Follow-Up Studies , Humans , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Prognosis , Proportional Hazards Models , Survival RateABSTRACT
In the last years, fludarabine (FLU) alone or in combination with other drugs has been reported to be effective in the treatment of previously untreated low-grade non-Hodgkin's lymphomas (LG-NHL). We report on the therapeutic efficacy and toxicity of a combination of FLU, idarubicin and cyclophosphamide (FLUIC regimen) in untreated non-follicular LG-NHL. We administered a three-drug combination of FLU (25 mg/m2 i.v. on days 1 to 3), idarubicin (14 mg/m2 i.v. on day 1) and cyclophosphamide (200 mg/m2 i.v. on days 1 to 3) to treat 41 young, previously untreated patients with non-follicular LG-NHL. Chemotherapy was repeated every 4 weeks for a total of 6 cycles. Among 41 patients, 24 (59%) were diagnosed with small lymphocytic, 10 (24%) with immnocytoma, and 7 (17%) with marginal zone subtypes. Nineteen (46%) patients achieved complete response (CR) and 21 (51%) partial response, while the remaining 1 (3%) showed no benefit from the treatment. With respect to histology, we observed CR rates of 38% for the small lymphocytic subtype, 40% for the immunocytoma subtype, and 86% for the marginal zone subtype. Estimated 42-month overall survival and relapse-free survival rates were 64% and 100%, respectively. Hematologic grade 3-4 toxicity was seen in 9 (22%) patients; no opportunistic infection or death was associated with administration of the FLUIC regimen. These preliminary data suggest that FLUIC is a very active, well-tolerated regimen for young, untreated patients with advanced non-follicular LG-NHL.
Subject(s)
Aging/physiology , Cyclophosphamide/therapeutic use , Idarubicin/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Vidarabine/analogs & derivatives , Vidarabine/therapeutic use , Adult , Aged , Cyclophosphamide/adverse effects , Drug Therapy, Combination , Female , Humans , Idarubicin/adverse effects , Male , Middle Aged , Treatment Outcome , Vidarabine/adverse effectsABSTRACT
PURPOSE: Promising new therapeutic options for follicular lymphoma (FL) include fludarabine plus mitoxantrone (FM) and the mouse/human anti-CD20 antibody, rituximab. We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) front-line chemotherapy with and without sequential rituximab. PATIENTS AND METHODS: All previously untreated CD20(+) FL patients presenting in 15 Italian cooperative institutions from October 1999 were randomly allocated to FM or CHOP. Following clinical or molecular restaging, patients in complete remission (CR) with bcl-2/IgH negativity (CR(-)) received no further treatment; those in CR with bcl-2/IgH positivity (CR(+)) received rituximab, as did those in partial remission (PR) with bcl-2/IgH negativity (PR(-)) or positivity (PR(+)); nonresponders (NR subgroup) were off study. RESULTS: After chemotherapy, the FM arm achieved higher rates of CR (68% [49 of 72 patients] v 42% [29 of 68 patients]; P =.003) and CR(-) (39% [28 of 72 patients] v 13 of 68 patients [19%]; P =.001). Rituximab elicited CR(-) in 55 of 95 treated patients (58%). The final CR(-) rate was higher in the FM arm (71% [51 of 72 patients] v 51% [35 of 68 patients]; P =.01). However, with a median follow-up of 19 months (range, 9 to 37 months), no statistically significant difference was found among the various study arms in terms of both progression-free (PFS) and overall survival (OS). CONCLUSION: These results indicate that FM is superior to CHOP for front-line treatment of FL and that rituximab is an effective sequential treatment option. However, they also confirm that this superiority is unlikely to translate into either better PFS or OS.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Follicular/drug therapy , Administration, Oral , Adult , Aged , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Agents/pharmacology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cyclophosphamide/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Drug Administration Schedule , Female , Humans , Infusions, Intravenous , Lymphoma, Follicular/pathology , Male , Middle Aged , Prednisone/administration & dosage , Rituximab , Treatment Outcome , Vincristine/administration & dosageABSTRACT
BACKGROUND AND OBJECTIVES: This multinational retrospective study compares the outcomes of patients with primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis after first-generation (dose-intensive regimens), third-generation (alternating regimens) and high-dose chemotherapy strategies, frequently with adjuvant radiation therapy. DESIGN AND METHODS: Between August 1981 and December 1999, a total of 426 previously untreated patients with confirmed diagnosis were enrolled in 20 institutions to receive combination chemotherapy with either first generation (CHOP or CHOP-like) regimens, third generation (MACOP-B, VACOP-B, ProMACE CytaBOM) regimens or high-dose chemotherapy (HDS/ABMT). RESULTS: With chemotherapy, complete response (CR) rates were 49% (50/105), 51% (142/277) and 53% (23/44) with first generation, third generation and high-dose chemotherapy strategies, respectively; partial response (PR) rates were 32%, 36% and 35%, respectively. All patients who achieved CR and 124/142 (84%) with PR had radiation therapy on the mediastinum. The final CR rates became 61% for CHOP/CHOP-like regimens, 79% for MACOP-B and other regimens, and 75% for HDS/ABMT. After median follow-ups from attaining CR of 48.5 months for CHOP/CHOP-like regimens, 51.7 months for MACOP-B type regimens and 32.4 months for HDS/ABMT, relapses occurred in 15/64 (23%), 27/218 (12%) and 0/33 (0%) patients, respectively. Projected 10-year progression-free survival rates were 35%, 67% and 78%, respectively (p=0.0000). Projected 10-year overall survival rates were 44%, 71% and 77%, respectively (p=0.0000), after median follow-ups from diagnosis of 52.3 months, 54.9 months and 35.8 months, respectively. INTERPRETATION AND CONCLUSIONS: In patients with PMLBCL with sclerosis, MACOP-B plus radiation therapy may be a better strategy than other treatments; these retrospective data need to be confirmed by prospective studies. The encouraging survival results after high dose chemotherapy require confirmation in selected high-risk patients.